Funded Tech Companies
DiogenX
Wondering who provided funding to DiogenX? Eli Lilly and Company, Boehringer Ingelheim Venture Fund and Roche Venture Fund joined the equity holders in this innovative biopharmaceutical company.
Company Overview
Company Name
DiogenX
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
180 avenue du Prado
Marseille, 13008
FR
Marseille, 13008
FR
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
DiogenX is a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes. Founded in 2020 based on the research of leading type 1 (T1D) diabetes scientist Patrick Collombat on pancreatic beta cell regeneration, DiogenX is developing first-in-class recombinant proteins designed for the treatment of T1D.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
5/10/2023
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Benjamin Charles
Co-Founder
Patrick Collombat
Co-Founder
Jean Tranié
Company Investors
- Eli Lilly and Company
- Boehringer Ingelheim Venture Fund
- Roche Venture Fund
- OMNES Capital
- AdBio Partners
- JDRF T1D Fund
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
Our data comes from VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs